GE HealthCare Technologies Inc.
GEHC- Exchange
- Nasdaq
- Industry
- X-Ray Apparatus & Tubes & Related Irradiation Apparatus
- SEC CIK
- 0001932393
No open-market purchases or sales by GE HealthCare Technologies Inc. insiders were filed in the last 90 days; 1,237 institutions reported holding it in 13F filings for Q2 2026, worth $25.2B in total; 3 superinvestors hold it, including Harris Associates (Oakmark) and Trian Fund Management.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 29, 2026, 1:15 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Feb 4, 2026 | Feb 13, 2025 | Feb 6, 2024 |
| Revenue | $20.6B | $19.7B | $19.6B |
| Gross profit | $8.25B | $8.21B | $7.92B |
| Operating expenses | $5.49B | $5.58B | $5.49B |
| Research and development | $1.26B | $1.31B | $1.21B |
| Selling, general and administrative | $4.22B | $4.27B | $4.28B |
| Operating income | $2.76B | $2.63B | $2.44B |
| Income tax | $614.0M | $531.0M | $743.0M |
| Net income | $2.08B | $1.99B | $1.57B |
| EPS, basic | $4.56 | $4.37 | $3.05 |
| EPS, diluted | $4.55 | $4.34 | $3.03 |
| Weighted shares, basic | 456.0M | 456.0M | 455.0M |
| Weighted shares, diluted | 458.0M | 459.0M | 458.0M |
| Margins and growth | |||
| Gross margin | 40.0% | 41.7% | 40.5% |
| Operating margin | 13.4% | 13.3% | 12.5% |
| Net margin | 10.1% | 10.1% | 8.0% |
| Revenue growth, year over year | +4.8% | +0.6% | – |
| Net income growth, year over year | +4.6% | +27.1% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Feb 4, 2026 | Feb 13, 2025 | Feb 6, 2024 |
| Cash and equivalents | $4.49B | $2.87B | $2.49B |
| Inventory | $2.23B | $1.94B | $1.96B |
| Total current assets | $12.5B | $9.90B | $9.41B |
| Property, plant and equipment | – | – | $2.14B |
| Goodwill | $13.5B | $13.1B | $12.9B |
| Intangible assets | $1.13B | $1.08B | $1.25B |
| Total assets | $36.9B | $33.1B | $32.5B |
| Accounts payable | $3.25B | $3.02B | $2.95B |
| Short-term debt | $508.0M | $1.50B | $1.01B |
| Total current liabilities | $9.11B | $9.55B | $8.98B |
| Long-term debt | $9.49B | $7.45B | $8.44B |
| Total liabilities | $26.3B | $24.4B | $25.1B |
| Shareholders' equity | $10.4B | $8.46B | $7.14B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Feb 4, 2026 | Feb 13, 2025 | Feb 6, 2024 |
| Capital expenditures | $482.0M | $401.0M | $387.0M |
| Stock-based compensation | $130.0M | $125.0M | $114.0M |
| Dividends paid | $64.0M | $55.0M | $41.0M |
| Share buybacks | $200.0M | – | – |
| Investing cash flow | -$1.05B | -$914.0M | -$558.0M |
| Financing cash flow | $617.0M | -$573.0M | -$478.0M |
| Net change in cash | $1.62B | $387.0M | $1.05B |
| Ratio | |||
| Stock-based compensation, % of revenue | 0.6% | 0.6% | 0.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 21, 2026 | 452.1M | −0.7% | SEC |
| Jul 22, 2026 | 451.7M | −1.1% | SEC |
| Apr 22, 2026 | 454.9M | −0.7% | SEC |
| Jan 28, 2026 | 455.7M | −0.3% | SEC |
| Oct 22, 2025 | 455.5M | −0.3% | SEC |
| Jul 23, 2025 | 456.6M | 0.0% | SEC |
| Apr 23, 2025 | 457.9M | +0.3% | SEC |
| Feb 6, 2025 | 457.3M | +0.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.